RETA Research

Weight & Metabolism Observations

RETA has been examined in Phase 2 research trials. Published findings suggest:

  • Study subjects receiving the 12 mg dose showed average weight reductions of 24.2% over 48 weeks, compared to 2.1% in the control group

  • RETA demonstrated greater observed effects than semaglutide in comparative research

  • Observed outcomes were comparable to results reported in semaglutide and tirzepatide studies

Blood Sugar Observations

In research involving study subjects with Type 2 diabetes:

  • HbA1c reductions of up to 2.2% were observed

  • This effect is associated with RETA’s activity across multiple receptor pathways

Mechanism of Action

Research suggests RETA activates three receptor types:

  • GLP-1 Receptors

    • Associated with insulin release, gastric emptying rates, and satiety signaling in study models

  • GIP Receptors

    • Associated with insulin production and improved insulin sensitivity in laboratory observations

  • Glucagon Receptors

    • Associated with increased energy expenditure and enhanced fat oxidation in metabolic studies

Cardiometabolic & Organ Function Observations

Published research suggests observations beyond weight-related parameters, including:

  • Changes in lipid markers, including triglycerides, LDL, and VLDL

  • Observed blood pressure changes in diabetic and obese study groups

  • Improvements in kidney function markers, including filtration rates

  • Reductions in liver enzyme levels (ALT) and hepatic fat content in study models

Referenced Citations

  1. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544.

  2. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. N Engl J Med. 2023;389(6):514–526.

  3. Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881.

  4. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(8):1234–1247.

  5. Nauck MA, et al. Incretin-based therapies for treatment of type 2 diabetes: a meta-analysis of glycaemic, body weight and hypoglycemia effects. Diabetes Obes Metab. 2021.

  6. Gastaldelli A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes. Diabetes Obes Metab. 2022.

  7. Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial. Diabetologia. 2022.